Former Novo chairman Göran Ando joins the board as Tessa bags $50M in additional funding
As Tessa Therapeutics preps a pivotal late-stage trial readout and ramps up clinical activity for early-stage assets, it will be joined by a high profile …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.